Related Experiment Video

Updated: Jun 11, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

PI3K inhibitors in cardiovascular disease

Andreas Eisenreich1, Ursula Rauch

  • 1Charitè - Universitätsmedizin Berlin, Campus Benjamin Franklin, Centrum für Herz- und Kreislaufmedizin, 12200 Berlin, Germany. andreas.eisenreich@charite.de

Cardiovascular Therapeutics
|July 15, 2010
PubMed

Insights

Phosphoinositide 3-kinases (PI3Ks) are crucial in cardiovascular disease development. Targeting PI3K isoforms with drugs offers new therapeutic strategies for treating these conditions.

Area of Science:

  • Cardiovascular Science
  • Molecular Biology
  • Pharmacology

Background:

  • Cardiovascular diseases are a leading cause of global mortality.
  • Phosphoinositide 3-kinases (PI3Ks) regulate vital cellular functions implicated in cardiovascular pathogenesis.
  • Class I PI3Ks, with isoforms α, β, δ, and γ, have distinct roles in health and disease.

Purpose of the Study:

  • To review the pathophysiologic role of class I PI3Ks in cardiovascular diseases.
  • To explore the therapeutic potential of pharmacological PI3K inhibitors for cardiovascular conditions.

Main Methods:

  • Review of existing literature on PI3K isoforms and cardiovascular diseases.
  • Analysis of data from studies utilizing isoform-selective, isoform-preferring, and pan-PI3K inhibitors.
  • Synthesis of knowledge on PI3K functions in cellular processes relevant to cardiovascular health.

Main Results:

  • Class I PI3Ks significantly influence cell migration, translation, survival, metabolism, vascular homeostasis, and thrombogenicity.
  • Pharmacological inhibitors have enhanced understanding of individual PI3K isoform functions.
  • Targeting specific PI3K isoforms presents novel therapeutic avenues.

Conclusions:

  • Class I PI3Ks are key players in the pathophysiology of cardiovascular diseases.
  • Pharmacological inhibition of PI3K isoforms holds promise for novel cardiovascular therapies.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...